KR101241050B1 - Composition containing ginseng berry extract for improving sexual function - Google Patents
Composition containing ginseng berry extract for improving sexual function Download PDFInfo
- Publication number
- KR101241050B1 KR101241050B1 KR1020110012261A KR20110012261A KR101241050B1 KR 101241050 B1 KR101241050 B1 KR 101241050B1 KR 1020110012261 A KR1020110012261 A KR 1020110012261A KR 20110012261 A KR20110012261 A KR 20110012261A KR 101241050 B1 KR101241050 B1 KR 101241050B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- ginseng fruit
- nitric oxide
- fruit extract
- arginine
- Prior art date
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 74
- 241000208340 Araliaceae Species 0.000 title claims abstract description 73
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 73
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 73
- 239000000284 extract Substances 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 230000036299 sexual function Effects 0.000 title abstract description 16
- 235000021028 berry Nutrition 0.000 title description 2
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 56
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 33
- 229930064664 L-arginine Natural products 0.000 claims abstract description 31
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 31
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 6
- 201000001881 impotence Diseases 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 122
- 238000004519 manufacturing process Methods 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 21
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 17
- 210000005226 corpus cavernosum Anatomy 0.000 abstract description 9
- 210000003899 penis Anatomy 0.000 abstract description 9
- 210000002460 smooth muscle Anatomy 0.000 abstract description 8
- 239000000758 substrate Substances 0.000 abstract description 8
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract description 7
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract description 7
- 235000002789 Panax ginseng Nutrition 0.000 description 17
- 229940107131 ginseng root Drugs 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 230000018052 penile erection Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 6
- 229930182494 ginsenoside Natural products 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 229940089161 ginsenoside Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 201000001880 Sexual dysfunction Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 231100000872 sexual dysfunction Toxicity 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000004648 relaxation of smooth muscle Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000003954 umbilical cord Anatomy 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside Rg2 Natural products O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 2
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BEVHTVRRVVEMEF-UHFFFAOYSA-N [6'-acetyloxy-4-amino-2',7'-difluoro-5-(methylamino)-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl] acetate Chemical compound C12=CC(F)=C(OC(C)=O)C=C2OC2=CC(OC(C)=O)=C(F)C=C2C21OC(=O)C1=C(N)C(NC)=CC=C21 BEVHTVRRVVEMEF-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009539 inhibitory neurotransmission Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0606—Arginine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
본 발명은 인삼열매 추출물을 함유하는 남성의 성기능 개선용 조성물에 관한 것으로서, 보다 상세하게는 본 발명의 조성물은 인삼열매 추출물을 유효성분으로 함유함으로써 혈관내피세포에서의 일산화질소(NO) 생성 증가효과를 나타내어, 음경해면체 평활근을 이완시켜 음경의 발기 증진을 통해 남성 성기능을 개선시킬 수 있으며, 또한 일산화질소 생성 효소(Nitric Oxide Synthase)의 기질인 L-아르기닌을 인삼열매 추출물과 동시에 사용함으로써 일산화질소 생성 효과를 더욱 상승시킬 수 있다. The present invention relates to a composition for improving sexual function in males containing ginseng fruit extract, and more particularly, the composition of the present invention increases the production of nitric oxide (NO) in vascular endothelial cells by containing ginseng fruit extract as an active ingredient. It is possible to relax the corpus cavernosum smooth muscle to improve male sexual function through the enhancement of penis erection, and also to produce nitrogen monoxide by simultaneously using L-arginine, which is a substrate of nitric oxide synthase The effect can be further enhanced.
Description
본 발명은 인삼열매 추출물을 유효성분으로 함유하는 남성의 성기능 개선용 조성물에 관한 것으로서, 보다 상세하게는 인삼의 지상부 중에서 인삼근과 차별적 성분과 조성을 갖는 인삼열매 추출물을 유효성분으로 함유함으로써 혈관내피세포에서의 일산화질소(NO) 생성 증가효과를 나타내어 음경해면체 평활근을 이완시켜 음경의 발기 증진을 통해 남성 성기능을 개선시키는 조성물에 관한 것이다.
The present invention relates to a composition for improving sexual function in men containing a ginseng fruit extract as an active ingredient, and more specifically, by containing a ginseng fruit extract having a different ingredient and composition from ginseng root in the ground of ginseng as an active ingredient, vascular endothelial cells. It relates to a composition for improving male sexual function through the enhancement of the erection of the penis to relax the corpus cavernosum smooth muscle by showing the effect of increasing the production of nitric oxide (NO) in.
인삼(Panax ginseng C.A. Meyer)은 오가피과 인삼속에 속하는 식물로 한국, 중국 및 일본 등지에서 2,000여 년 전부터 사용되어 온 생약으로, 경험적으로 질병을 예방하고 수명을 연장시킬 목적으로 사용되어 왔으며, 지금까지 알려진 인삼의 효능 및 효과는 중추신경계에 대한 작용, 항발암 작용, 항암활성 작용, 면역기능 조절 작용, 항당뇨 작용, 간기능 항진효능, 심혈관 장해개선, 항동맥경화 작용, 혈압조절 작용, 갱년기 장애 개선, 골다공증에 미치는 효과, 항스트레스 작용, 항피로 작용, 항산화 활성 및 노화억제 효능 등이 알려져 있다(최신고려인삼 '성분 및 효능편', 한국인삼연초연구원, 56-112, 1996).Ginseng (Panax ginseng CA Meyer) is a plant belonging to the genus Ogapiaceae ginseng, which has been used in Korea, China, and Japan for more than 2,000 years, and has been used to prevent disease and extend life. The effects and effects of ginseng on the central nervous system, anti-carcinogenic, anti-cancer, immune-modulatory, anti-diabetic, hepatic anti-inflammatory effect, cardiovascular disorders, anti-arteriosclerosis, blood pressure control, menopausal disorders , Effects on osteoporosis, antistress action, anti-fatigue, antioxidant activity and anti-aging effects are known (latest ginseng 'components and efficacy', Korea Ginseng and Tobacco Research Institute, 56-112, 1996).
인삼의 대표적 생리활성 성분인 진세노사이드(Ginsenoside)는 인삼의 지상 및 지하부에 고르게 분포되어 있으며, 특히 인삼근(뿌리), 인삼엽 및 인삼열매 등 부위에 따라 진세노사이드 함량뿐만 아니라 조성도 다른 것으로 알려져 있다(Attele AS et al, Biochem Pharmacol, 58; 1685-1693, 1999). 그 중에서도 특히 인삼열매는 인삼근(뿌리)과 다른 진세노사이드 성분 함량과 성분을 가지며, 이를 바탕으로 항당뇨 효능에 있어서 인삼근보다 우수한 결과를 나타내는 것으로 보고되었다(Dey L. et al., Phytomedicine, 10; 600-605, 2003).Ginsenoside, a representative physiologically active ingredient of ginseng, is distributed evenly in the ground and underground parts of ginseng. Especially, ginsenoside content and composition are different depending on the parts such as ginseng root (root), ginseng leaf and ginseng fruit. (Attele AS et al, Biochem Pharmacol, 58; 1685-1693, 1999). Among them, ginseng berry has the content and composition of ginsenoside and other ginsenosides, and it has been reported that the ginseng fruit has better results than ginseng root in antidiabetic effect (Dey L. et al., Phytomedicine , 10; 600-605, 2003).
L-아르기닌은 화학식 C6H14N4O2로 된 염기성 아미노산으로 분자량 174.21이며, 루피누스(콩의 일종)의 싹튼 것으로부터 단리되었다. L-아르기닌은 단백질을 구성하는 아미노산의 하나로서 존재하며, 어류의 정자에 존재하는 단백질 프로타민에 속하고, 식물 종자 속에서 유리상태로 존재한다. 또한 생체 내의 대사 경로로서는 요산생성경로(오르니틴 회로)의 구성성분이며, 아르기나아제의 작용에 의하여 요소와 오르니틴으로 분해된다. 시트룰린과 아스파라긴산으로부터 생성되며, 성인에게는 비필수 아미노산이지만, 유아에게는 필수 아미노산이다.L-arginine is a basic amino acid having the formula C 6 H 14 N 4 O 2 , having a molecular weight of 174.21, isolated from the sprouting of lupine. L-arginine exists as one of the amino acids constituting the protein, belongs to the protein protamine in fish sperm and is free in plant seeds. In addition, as a metabolic pathway in vivo, it is a component of the uric acid production pathway (ornithine cycle), and is broken down into urea and ornithine by the action of arginase. Produced from citrulline and aspartic acid, it is a non-essential amino acid for adults but an essential amino acid for infants.
NO-니트로-L-아르기닌은 일산화질소(NO: nitric oxide) 합성 효소의 저해제인 것으로 알려져 있으며, NO-니트로-L-아르기닌이 혈관의 이완을 방해할 수 있음을 보여주는 연구가 있다. 그러나, NO-니트로-L-아르기닌의 저해효과는 L-아르기닌(3×10-3 mol/L)의 존재 하에 역전될 수 있음을 보여주는 연구가 있다(Simonsen et al., Nitric oxide is involved in the inhibitory neurotransmission and endothelium-dependent relaxations of human small penile arteries, Clin Sci. 92:3, 265-75). 이 연구는 L-아르기닌이 일산화질소 합성효소를 위한 효과적인 기질이 될 수 있고, 혈관에서의 일산화질소 유리를 자극할 수 있음을 제안하고 있다.NO-nitro-L-arginine is known to be an inhibitor of nitric oxide (NO) synthase, and there is research showing that NO-nitro-L-arginine can interfere with blood vessel relaxation. However, studies have shown that the inhibitory effects of NO-nitro-L-arginine can be reversed in the presence of L-arginine (3 × 10 -3 mol / L) (Simonsen et al., Nitric oxide is involved in the inhibitory neurotransmission and endothelium-dependent relaxations of human small penile arteries, Clin Sci. 92: 3, 265-75). The study suggests that L-arginine can be an effective substrate for nitric oxide synthase and can stimulate nitric oxide release in blood vessels.
남성의 성기능은 성적욕구, 음경의 발기, 사정 및 극치감으로 이루어지는 데, 이는 신경계, 내분비계 및 혈관계의 복합적인 생리반응에 의해 결정되며, 이중 하나라도 이상이 있으면 성기능 장애의 원인이 될 수 있다. 이러한 성기능 장애는 10여 년 전만 해도 대부분 심인성 원인으로 여겨졌지만, 현대 의학의 발달로 성기능 장애 환자의 약 50% 이상에서 혈관계, 신경계 및 내분비계 질환, 당뇨병, 고혈압, 약물복용 등의 다양한 원인에 의한 것으로 밝혀지고 있다. 최근 포스포디에스테라제V(phosphodiesterase V) 억제제인 실데나필(sildenafil)이 성기능 장애 치료에서 많은 관심을 모으고 있으나, 이러한 치료법은 화학약품을 이용하여 일시적인 발기를 유발시키는 방법으로 가격이 높고 두통, 혈압증가, 심장 마비 등 부작용이 많다. 특히 심장병을 가중시켜 사망하는 경우가 적지 않게 보고되고 있다. 따라서 인체의 본능적인 발기기능을 증강시키는 안전하고 유효한 성기능장애 치료제가 개발되어야 할 실정이며, 최근의 추세는 음경해면체 평활근에서 강한 이완작용을 나타내는 신호전달물질인 일산화질소 및 cGMP의 생성을 증가시켜 음경해면체의 발기를 증진시키는 성기능 개선 치료제를 개발하는 데 관심이 모아지고 있다.Male sexual function is composed of sexual desire, erection of the penis, ejaculation and extreme sensation, which is determined by the complex physiological reactions of the nervous system, endocrine system and vascular system. Most of the sexual dysfunction was considered to be a psychogenic cause only a decade ago, but due to the development of modern medicine, about 50% of patients with sexual dysfunction are caused by various causes such as vascular, nervous and endocrine diseases, diabetes, hypertension, and drug use. It turns out. Recently, sildenafil, a phosphodiesterase V inhibitor, has attracted much attention in the treatment of sexual dysfunction, but such treatment is a method of causing temporary erection using chemicals, and has a high price, headache, and increased blood pressure. There are many side effects such as heart attack. In particular, a number of deaths due to aggravating heart disease have been reported. Therefore, a safe and effective treatment for sexual dysfunction that enhances the body's instinctive erectile function should be developed, and the recent trend is to increase the production of nitric oxide and cGMP, which are strong signaling agents in the cavernous smooth muscle, penis. There is a growing interest in developing therapeutics for sexual function that enhances the erection of cavernous bodies.
음경 발기 과정 중 일어나는 변화는 복잡하며 말초 및 중추 신경계, 내분비계를 관여시키는 고도의 통합된 조절을 필요로 한다. 해면체 평활근 수축은 시냅수 후 α1 아드레날린성 수용체의 활성화를 통하여 교감 신경 노르아드레날린성 신경 자극에 의해 조절되고, 발기 부전증은 해면체의 내인성 평활근 긴장의 증가와 관련될 수 있다. 그러나, 음경 평활근 이완의 과정은 비아드레날린성, 비콜린성(NANC) 신경 전달에 의해 부분적으로 매개되며, 음경 해면체 평활근의 긴장이 감소되는 것은 일산화질소가 해면체의 이완을 유도하기 때문이다. 성적 흥분 중 일산화질소는 뉴런 및 내피로부터 방출되고 평활근 세포 및 내피에 위치하는 가용성 구아닐레이트 시클라제(sGC)에 결합하여 그것을 활성화시켜서, 세포내 시클릭구아노신 3'-, 5'-모노포스페이트(cGMP) 수준을 상승시킨다. 이 cGMP 수준의 상승은 단백질 키나아제 G 활성화가 관여된다고 생각되지만, 알려지지 않은 기전(Ca2 +-활성화 K+-채널의 활성화에 기인할 가능성이 있음)을 통해 세포내 칼슘 농도의 감소로 인한 해면체의 이완을 유도한다(Chuang et al., cGMP mediates corpus cavernosum smooth muscle relaxation with altered cross-bridge function. Life Sci. 1998;63(3):185-94). The changes that occur during the penile erection process are complex and require a high degree of integrated control involving the peripheral and central nervous and endocrine systems. Cavernous smooth muscle contraction is regulated by sympathetic noradrenergic nerve stimulation through activation of α1 adrenergic receptors after synapses, and erectile dysfunction may be associated with an increase in the endogenous smooth muscle tension of the cavernous body. However, the process of penile smooth muscle relaxation is partially mediated by non-drenergic, noncholinergic (NANC) neurotransmission, and the decrease in the tension of the corpus cavernosum smooth muscle is because nitrogen monoxide induces the relaxation of the corpus cavernosum. During sexual arousal, nitric oxide is released from neurons and endothelium and binds to and activates soluble guanylate cyclase (sGC) located in smooth muscle cells and endothelium, thereby intracellular cyclic guanosine 3'-, 5'-monophosphate raises cGMP levels. Increase of the cGMP level is the protein kinase G thought that activation is involved, but, unknown mechanism due to a decrease in intracellular calcium concentration cell with the (Ca 2 + - Likely to be due to the activation of the channel-activated K +) cavernosum Induce relaxation (Chuang et al., CGMP mediates corpus cavernosum smooth muscle relaxation with altered cross-bridge function.Life Sci. 1998; 63 (3): 185-94).
따라서 일산화질소 생성효소의 기질인 L-아르기닌과 혈관에서 일산화질소(NO)의 생성을 촉진시켜 주는 물질의 복합적 사용은 해면체 내에서 일산화질소의 충분한 유리를 자극하여 평활근 이완을 야기 및 지속시켜 혈액을 유입하고, 발기 부전을 경감시키도록 할 수 있다는 점에서 크게 이점이 될 것이다.
Therefore, the combination of L-arginine, a substrate of nitric oxide synthase, and a substance that promotes the production of nitric oxide (NO) in blood vessels stimulates the release of nitrogen monoxide in the cavernous body, causing and sustaining smooth muscle relaxation. It will be a great advantage in that it can induce and reduce erectile dysfunction.
이에, 본 발명자들은 인삼의 지하부인 인삼근 외에도 지상부인 인삼열매 추출물의 여러 가지 생리활성을 연구하던 중 인삼열매 추출물이 일반적인 인삼 및 홍삼과는 다른 성분과 조성에 의한 남성 성기능 개선 효능이 있음을 발견하였으며, 또한 일산화질소 생성효소의 기질인 L-아르기닌과 복합적으로 사용하였을 때 상기 효과가 상승되는 것을 발견하고 본 발명을 완성하게 되었다. Accordingly, the present inventors found that the ginseng fruit extract has a male sexual function-improving effect by different ingredients and compositions from general ginseng and red ginseng, while studying various physiological activities of ginseng fruit extracts in the ground part as well as ginseng root which is the underground part of ginseng. In addition, it was found that the effect is increased when used in combination with L-arginine, a substrate of nitric oxide synthase, and completed the present invention.
따라서, 본 발명의 목적은 음경해면체의 평활근에서 강한 이완작용을 나타내는 신호전달물질인 일산화질소(NO) 생성 증가효과를 나타내어 음경의 발기증진을 통해 남성 성기능을 개선시키는 조성물을 제공하는 것이다.
Accordingly, it is an object of the present invention to provide a composition for improving male sexual function through an increase in the erection of the penis by exhibiting an effect of increasing the production of nitric oxide (NO), which is a signaling material showing a strong relaxation effect in the smooth muscle of the corpus cavernosum.
상기한 목적을 달성하기 위하여, 본 발명은 인삼열매 추출물을 유효성분으로 함유하는 남성 성기능 개선용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for improving male sexual function containing a ginseng fruit extract as an active ingredient.
또한, 본 발명은 상기 인삼열매 추출물 유효성분에 L-아르기닌을 더 포함하는 남성 성기능 개선용 조성물을 제공한다.
The present invention also provides a composition for improving male sexual function, further comprising L-arginine in the ginseng fruit extract active ingredient.
본 발명의 인삼열매 추출물은 혈관내피세포에서 일산화질소(NO) 생성을 증가시킴으로써, 일산화질소(NO) 생성에 의해 음경의 발기를 증진할 가능성을 제시해 준다. 또한 이러한 효과는 일산화질소 생성효소의 기질인 L-아르기닌과 복합적으로 사용하였을 때 상승할 수 있다. 따라서 인삼열매 추출물 및 L-아르기닌을 유효성분으로 함유하는 조성물은 남성 성기능 개선 효과를 제공할 수 있다.
Ginseng fruit extract of the present invention increases the production of nitric oxide (NO) in vascular endothelial cells, suggesting the possibility of promoting the erection of the penis by the production of nitric oxide (NO). This effect may also be elevated when used in combination with L-arginine, a substrate of nitric oxide synthase. Therefore, the composition containing ginseng fruit extract and L-arginine as an active ingredient may provide a male sexual function improving effect.
도 1은 인삼열매 추출물(실시예 1)과 인삼근 추출물(비교예 1)의 진세노사이드 성분을 분석한 결과를 나타내는 그래프이다.
도 2는 L-아르기닌, 홍삼 추출물 및 인삼열매 추출물의 혈관내피세포에서의 일산화질소(NO) 생성 촉진 효과를 공초점 레이저 현미경으로 찍은 사진으로 나타낸 것이다.
도 3은 L-아르기닌, 홍삼 추출물 및 인삼열매 추출물의 혈관내피세포에서의 일산화질소(NO) 생성 촉진 효과를 상대적 형광 강도로 나타낸 그래프이다.
도 4는 인삼열매 추출물과 L-아르기닌의 일산화질소 생성 상승효과를 상대적 형광 강도로 나타낸 그래프이다.1 is a graph showing the results of analyzing ginsenoside components of ginseng fruit extract (Example 1) and ginseng root extract (Comparative Example 1).
Figure 2 shows a photograph taken with a confocal laser microscope of the effect of promoting the production of nitric oxide (NO) in the vascular endothelial cells of L-arginine, red ginseng extract and ginseng fruit extract.
3 is a graph showing the relative fluorescence intensity of the effect of promoting the production of nitric oxide (NO) in vascular endothelial cells of L-arginine, red ginseng extract and ginseng fruit extract.
Figure 4 is a graph showing the relative fluorescence intensity synergistic effect of nitric oxide production of ginseng fruit extract and L-arginine.
본 발명은 혈관내피세포에서의 일산화질소(NO) 생성증가효과를 통해 음경의 발기를 증진시킴으로써 남성 성기능 개선 효능의 조성물을 제공하기 위하여 유효성분으로서 인삼열매 추출물을 함유하며, 여기에 L-아르기닌을 더 함유할 수 있다.The present invention contains a ginseng fruit extract as an active ingredient in order to provide a composition for improving male sexual function by enhancing the erection of the penis through the effect of increasing the production of nitric oxide (NO) in vascular endothelial cells, wherein L-arginine It may contain more.
남성의 성기능을 개선하기 위해서는 음경해면체 평활근에서 강한 이완작용을 나타내게 함으로써 음경발기를 촉진시켜야 한다. 그 작용기전은 일산화질소(NO)의 생성을 증가시키는 것에 집중되고 있다. 이와 관련하여 산화 질소가 음경발기에 중요한 역할을 하는 것이 동물 실험에서 밝혀졌다. 혈관내피세포에서 분비되는 산화질소의 생성이 성적 자극 하에 음경의 부교감신경 말초에서 또한 증가된다. 일산화질소는 구아닐레이트 사이클라제(guanylate cyclase)를 활성화시켜 구아노신 트리포스페이트(GTP)를 사이클릭 구아노신 모노포스페이트(cGMP)로 전환되게 한다. 여기에서 발생된 cGMP는 해면체의 평활근 및 음경동맥의 이완을 생기게 하는 신호를 제공하여 음경의 발기를 유도하게 된다. 따라서 음경발기가 지속되기 위해서는 일산화질소의 생성이 중요하다고 할 수 있다. In order to improve male sexual function, it is necessary to promote penile erection by showing strong relaxation in the corpus cavernosum smooth muscle. The mechanism of action is focused on increasing the production of nitrogen monoxide (NO). In this connection, nitric oxide has been shown to play an important role in penile erection in animal experiments. The production of nitric oxide secreted by vascular endothelial cells is also increased in the parasympathetic peripheral of the penis under sexual stimulation. Nitrogen monoxide activates guanylate cyclase to convert guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). The cGMP generated here induces erection of the penis by providing a signal that causes relaxation of the cavernous smooth muscle and penile artery. Therefore, the production of nitric oxide is important in order to sustain penile erection.
본 발명에 의한 남성 성기능 개선용 조성물은 조성물의 형태에 따라 인삼 열매 추출물을 조성물 총 중량에 대하여 0.01∼100 중량%로 혼합하는 것을 특징으로 한다. 또한 L-아르기닌과의 복합적 사용시에 L-아르기닌은 조성물 총 중량에 대하여 0.01∼99.9 중량%의 비율로 사용될 수 있다.The male sexual function improving composition according to the present invention is characterized in that the ginseng fruit extract is mixed in an amount of 0.01 to 100% by weight based on the total weight of the composition. In addition, when used in combination with L-arginine, L-arginine may be used in a ratio of 0.01 to 99.9% by weight based on the total weight of the composition.
또한, 상기 조성물은 정제, 환제, 단제, 캡슐제, 과립제, 산제, 연고제, 드링크제 또는 주사제의 형태로 약학 조성물 또는 식품 조성물로서 제형화할 수 있다.In addition, the composition may be formulated as a pharmaceutical composition or food composition in the form of tablets, pills, tablets, capsules, granules, powders, ointments, drinks or injections.
본 발명의 조성물은 통상적인 방법에 따라 약학 제형으로 제조될 수 있다. 제형의 제조에 있어서, 활성 성분을 담체와 함께 혼합 또는 희석하거나, 용기 형태의 담체 내에 봉입시키는 것이 바람직하다. 담체가 희석제로 사용되는 경우에는 활성 성분에 대한 담체, 부형제 또는 매질(medium)로 작용하는 고형, 반고형 또는 액상의 물질일 수 있다. 따라서, 제형은 정제, 환제, 분제, 새세이, 엘릭시르, 현탁제, 유제, 용액제, 시럽제, 에어로졸, 연질 또는 경질 젤라틴 캅셀제, 멸균 주사제, 멸균 분제 등의 형태일 수 있다.The compositions of the present invention can be prepared in pharmaceutical formulations according to conventional methods. In the preparation of the formulations, it is preferred that the active ingredient is mixed with or diluted with the carrier, or enclosed in a carrier in the form of a container. When the carrier is used as a diluent, it may be a solid, semisolid or liquid substance which acts as a carrier, excipient or medium for the active ingredient. Thus, the formulations may be in the form of tablets, pills, powders, assays, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injectables, sterile powders and the like.
적합한 담체, 부형제 및 희석제의 예로는, 락토오스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제형은 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 포함할 수 있다. 본 발명의 조성물은 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 사용하여 제형화될 수 있다.Examples of suitable carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydride Oxybenzoate, talc, magnesium stearate and mineral oil. The formulations may additionally include fillers, anti-coagulants, lubricants, wetting agents, perfumes, emulsifiers, preservatives, and the like. Compositions of the present invention may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
본 발명의 약학 조성물은 경구, 경피, 피하, 정맥, 복강, 근육, 국소도포, 첩포 및 이온토포레시스(iontophoresis)를 포함한 여러 경로를 통해 투여될 수 있고, 이 중에서 국소 적용 및 경구투여가 바람직하다.The pharmaceutical composition of the present invention may be administered through several routes including oral, transdermal, subcutaneous, intravenous, abdominal, muscle, topical application, patch and iontophoresis, of which topical application and oral administration are preferred. Do.
사람의 경우, 활성 화합물의 통상적인 1일 투여량은 1 내지 100 mg/kg체중, 바람직하게는 5 내지 70 mg/kg체중의 범위일 수 있고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 활성 성분의 실제 투여량은 치료할 질환, 투여 경로, 환자의 연령, 성별 및 체중, 및 질환의 중증도 등의 여러 관련 인자에 비추어 결정되어야 하는 것으로 이해되어야 하며, 따라서, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.
In humans, a typical daily dosage of the active compound may range from 1 to 100 mg / kg body weight, preferably 5 to 70 mg / kg body weight, and may be administered once or in several doses. However, it should be understood that the actual dosage of the active ingredient should be determined in light of several relevant factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, and the severity of the disease, and therefore the dosage may be determined in any way. Nor does it limit the scope of the present invention.
이하 본 발명을 실시예에 의거하여 상세하게 설명하지만, 본 발명의 기술적 범위가 이들 실시예로 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to Examples, but the technical scope of the present invention is not limited to these Examples.
[실시예 1] 인삼 열매 추출물 제조Example 1 Preparation of Ginseng Fruit Extract
1. 인삼 열매 전처리1. Ginseng Fruit Pretreatment
생(生)인삼 열매를 수확하여 종자를 분리하여 제거한 후 인삼 열매의 과육과 과피를 일광건조 또는 열풍건조를 통하여 인삼 열매 건조원료를 제조하였다.
Raw ginseng fruit was harvested, seed was separated and removed, and then the ginseng fruit dried raw material was prepared by sun drying or hot air drying.
2. 인삼 열매 추출물 제조2. Ginseng Fruit Extract Manufacturer
인삼 열매 건조물 1 kg에 물 또는 주정 3 L를 가하여 상온 또는 환류 추출한 다음 여과한 후 40∼45℃에서 감압농축하여 인삼 열매 추출물 300 g을 얻었다.
Water or alcohol 3 L was added to 1 kg of dried ginseng fruit dried, followed by extraction at room temperature or reflux, followed by filtration and concentration under reduced pressure at 40 to 45 ° C. to obtain 300 g of ginseng fruit extract.
[비교예 1] 인삼근 추출물 제조Comparative Example 1 Preparation of Ginseng Root Extract
상기 실시예 1에서 인삼 열매 대신에 인삼근(뿌리)을 사용한 것을 제외하고 실시예 1과 동일한 방법으로 제조하였다.
Except for using ginseng root (root) instead of ginseng fruit in Example 1 was prepared in the same manner as in Example 1.
[시험예 1] 인삼 열매 추출물의 성분 비교Test Example 1 Component Comparison of Ginseng Fruit Extract
<인삼 열매와 인삼근의 진세노이드(인삼사포닌) 성분 분석><Analysis of Ginsenoid (Ginseng Saponin) in Ginseng Fruit and Ginseng Root>
실시예 1 및 비교예 1에서 각각 인삼 열매와 인삼근 추출물을 제조한 다음 이들 추출물에 에테르(ether)를 처리하여 지용성 성분을 제거한 후 부탄올(BuOH)로 조사포닌을 추출, 농축하여 HPLC를 통한 진세노이드 성분 분석을 실시하였으며, 그 결과를 도 1 및 하기 표 1에 나타내었다.In Example 1 and Comparative Example 1, respectively, ginseng fruit and ginseng root extract were prepared, and these extracts were treated with ether to remove fat-soluble components, followed by extracting and concentrating irradiated with butanol (BuOH), using HPLC. Noid component analysis was performed, and the results are shown in FIG. 1 and Table 1 below.
도 1 및 상기 표 1을 통해, 실시예 1에서 제조한 인삼 열매 추출물은 조사포닌 함량에 있어서 비교예 1에서 제조한 인삼근 추출물의 약 2배 함량을 가지고 있으며, 진세노사이드를 PD(Protopanaxadiol)계-"진세노사이드 Rb1, Rb2, Rc 및 Rd" 및 PT(Protopanaxatriol)계-"진세노사이드 Re, Rg1 및 Rg2"의 비율로 구분하였을 때 각각 0.73과 3.23으로 그 조성에 있어서 인삼 열매와 인삼근은 뚜렷한 차이 및 특징을 나타냄을 알 수 있다.
1 and Table 1, the ginseng fruit extract prepared in Example 1 has about 2 times the content of the ginseng root extract prepared in Comparative Example 1 in the content of irradiated phonoins, ginsenoside PD (Protopanaxadiol) Ginseng fruit and ginseng in the composition of 0.73 and 3.23, respectively, when divided into the ratios of "-ginsenoside Rb1, Rb2, Rc and Rd" and PT (Protopanaxatriol)-"ginsenoside Re, Rg1 and Rg2" It can be seen that the roots exhibit distinct differences and features.
<인삼 열매 추출물의 미네랄 성분 분석>Mineral Analysis of Ginseng Fruit Extract
실시예 1에서 제조한 인삼 열매 추출물이 인삼과는 다른 "과실"로서의 특징을 갖는 것임을 구분하기 위하여 비타민을 비롯한 미네랄 성분을 분석하였으며, 그 결과를 하기 표 2에 나타내었다. In order to distinguish that the ginseng fruit extract prepared in Example 1 has the characteristics of "fruit" different from ginseng, mineral components including vitamins were analyzed, and the results are shown in Table 2 below.
이상과 같이 본 발명에서 사용하는 인삼 열매의 성분적 특성은 인삼근보다 많은 인삼사포닌을 함유함과 동시에 사포닌 조성의 성질이 정반대이고, 또한 인삼근과 달리 열매로서 비타민과 미네랄 16종의 함량이 풍부함을 확인할 수 있었다.
As described above, the ginseng fruit used in the present invention contains more ginseng saponin than the ginseng root, and at the same time, the nature of the composition of saponin is opposite to that of the ginseng root. Could confirm.
상기 결과를 바탕으로 인삼열매 추출물의 남성 생식 기능 개선 효능에 대하여 실험하였다. 비교물질로서는 현재 남성 성기능 개선 기대효능의 건강식품으로 널리 사용되고 있는 소재인 홍삼 추출물을 사용하여 인삼 열매 추출물과의 효능을 비교하였다.
Based on the results, the effect of ginseng fruit extract on male reproductive function was tested. As a comparison material, red ginseng extract, which is widely used as a health food with the expected effect of improving male sexual function, was compared with ginseng fruit extract.
[비교예 2] 홍삼 추출물 제조Comparative Example 2 Preparation of Red Ginseng Extract
인삼 열매 추출물과 효능을 비교하게 위하여 홍삼 추출물을 제조하였다. 홍삼(수분함량 14%) 또는 홍삼 분말 1 kg에 물 또는 주정 6∼10 L를 가하여 상온/환류 추출을 3회 실시한 다음 통상의 방법으로 여과과정을 거친 후 감압농축하여 홍삼 추출물 약 250 g을 얻었다.
Red ginseng extract was prepared to compare the efficacy with the ginseng fruit extract. Water or alcohol 6-6 L was added to 1 kg of red ginseng (14% water content) or red ginseng powder, followed by extraction at room temperature / reflux three times, followed by filtration and concentrated under reduced pressure to obtain 250 g of red ginseng extract. .
[시험예 2] 인삼열매 추출물의 혈관내피세포에서의 일산화질소(NO) 생성 증가 효과Experimental Example 2 Effect of Ginseng Fruit Extract on the Production of Nitric Oxide (NO) in Endothelial Cells
인삼열매 추출물을 혈관내피세포에 처리하였을 때 음경발기에 중요한 신호전달물질로 알려진 일산화질소(NO)의 생성 증가를 관찰하였다. 이는 혈관내피세포에서 eNOS(endothelial nitric oxide synthase, 내피세포에서의 일산화질소 생성효소)에 의한 일산화질소(NO)의 생성증가가 혈관을 이완시켜 음경의 발기를 증진할 수 있기 때문이다. When ginseng fruit extract was treated with vascular endothelial cells, the production of nitric oxide (NO), which is an important signaling material for penile erection, was observed. This is because increased production of nitric oxide (NO) by endothelial nitric oxide synthase (eNOS) in vascular endothelial cells can relax blood vessels and promote penile erection.
구체적인 실험방법은 다음과 같다. The specific experimental method is as follows.
1. 탯줄에서 혈관내피세포의 분리 및 배양1. Isolation and Culture of Endothelial Cells from Umbilical Cord
내피세포는 혈관의 기저막(basement membrane) 상에 존재하고 있으며, 혈관의 가장 안쪽에 위치하여 혈액과 직접 접하고 있는 세포이다. 내피세포의 종류에는 여러 가지가 있는 데 그 중 가장 널리 분리 및 이용되는 세포로 인간탯줄기원의 내피세포(human umbilical vein endothelial cell; HUVEC)를 들 수 있다. Endothelial cells exist on the basement membrane of blood vessels, and are cells which are located at the innermost side of blood vessels and are in direct contact with blood. There are various types of endothelial cells, among which the most widely isolated and used cells include human umbilical vein endothelial cells (HUVECs).
HUVEC를 분리하기 위하여 먼저 탯줄(15∼20 cm)에 있는 정맥을 PBS로 잘 세척하여 혈액 응고물 등을 제거하였다. 다음으로 탯줄 정맥관의 양쪽 말단에 캐뉼라(cannular) 및 투 웨이 콕 마개(2-way stop cock)를 장치한 후 250 units/ml의 콜라겐 분해효소를 주입하여 37℃에서 5∼10분간 배양하고, 효소 활성에 의하여 기저막으로부터 HUVEC를 분리하였다. 사람의 탯줄정맥에서 얻어진 내피세포(HUVEC)는 20%(w/v) FBS, 100 units/ml의 페니실린, 100 ㎍/ml의 스트렙토마이신, 3 ng/ml의 bFGF(basic fibroblast growth factor) 및 5 units/ml의 헤파린을 함유한 M199 배지를 이용하여 젤라틴(gelatin)으로 코팅(coating)된 플레이트(plate) 및 플라스크(flask)에 옮겨서 37℃, 5% CO2 배양기에서 배양하였다.
In order to separate HUVECs, the veins in the umbilical cord (15-20 cm) were first washed well with PBS to remove blood coagulants. Next, cannular and 2-way stop cocks were installed at both ends of the umbilical vein tube, and 250 units / ml of collagenase was injected and incubated at 37 ° C. for 5 to 10 minutes. HUVECs were separated from the basement membrane by activity. Endothelial cells (HUVECs) obtained from human umbilical veins (20% (w / v) FBS, 100 units / ml penicillin, 100 μg / ml streptomycin, 3 ng / ml basic fibroblast growth factor) and 5 Transfer to plates and flasks coated with gelatin using M199 medium containing units / ml of heparin at 37 ° C., 5% CO 2 Lt; / RTI >
2. 혈관내피세포(HUVEC)에서의 일산화질소 생성 측정2. Measurement of nitric oxide production in vascular endothelial cells (HUVEC)
혈관내피세포를 젤라틴 코팅된 24 공평판 배양기(well plate)에 2.5×104 cells/well의 밀도로 배양하였으며, 세포는 성장 배지에서 12시간 동안 배양하였다. 혈관내피세포는 대조군과 L-아르기닌 처리군, 비교예 2의 홍삼 추출물(RG) 처리군, 실시예 1의 인삼열매 추출물(GB) 처리군으로 나누어 12시간 100 ㎍/mL 의 농도로 전처리 하였다. 내피세포는 37℃에서 FBS가 없는 M199 배지에 10 μmol/L DAF-FM 디아세테이트(diacetate)(Molecular Probe, OR)로 30분 동안 처리하였다. 혈관내피세포는 FBS가 없는 M199배지로 3번 씻어준 후, 패러렐 플레이트 플로우 챔버(parallel plate flow chamber)에 넣고, 수은등(mercury lamp)으로부터 분리된 빛으로 자극하였다. 여기(excitation) 파장은 488 nm 이었고, 일산화질소(NO)가 결합된 DAF는 515 nm에서 형광을 내었다. 사진은 공초점 레이저 현미경(Confocal laser microscope(Atto Bioscience, USA))으로 찍고, 형광의 밝기는 이미지프로 ㅍ플러스(age-Pro Plus) v4.5 소프트웨어(Media Cybernetics, San Diego, CA, USA)로 분석하였으며, 이는 도 2 및 도 3에 나타내었다. 도 2 및 도 3에서 con은 대조군, RG는 비교예 2의 홍삼 추출물 처리군, GB는 실시예 1의 인삼 열매 추출물 처리군을 의미하며, RG 50은 홍삼 추출물 50 ㎍/ml, RG 100은 홍삼추출물 100 ㎍/ml, L-arginine 250은 L- 아르기닌 250 μM, L-arginine 500은 L-아르기닌 500 μM, GB 50은 인삼열매 추출물 50 ㎍/ml, GB 100은 인삼열매 추출물 100 ㎍/ml를 처리한 것을 의미한다.Vascular endothelial cells were cultured at a density of 2.5 × 10 4 cells / well in a gelatin coated 24 well plate incubator, and the cells were incubated for 12 hours in growth medium. Vascular endothelial cells were pretreated at a concentration of 100 μg / mL for 12 hours, divided into control group, L-arginine treatment group, red ginseng extract (RG) treatment group of Comparative Example 2, and ginseng fruit extract (GB) treatment group of Example 1. Endothelial cells were treated for 30 minutes with 10 μmol / L DAF-FM diacetate (Molecular Probe, OR) in M199 medium without FBS at 37 ° C. Vascular endothelial cells were washed three times with M199 medium without FBS, placed in a parallel plate flow chamber, and stimulated with light separated from a mercury lamp. The excitation wavelength was 488 nm, and DAF bound with nitric oxide (NO) fluoresced at 515 nm. Photos are taken with a confocal laser microscope (Atto Bioscience, USA), and the fluorescence brightness is measured with image-Pro Plus v4.5 software (Media Cybernetics, San Diego, CA, USA). This was shown in Figures 2 and 3. In Figures 2 and 3 con is a control group, RG is a red ginseng extract treatment group of Comparative Example 2, GB means a ginseng fruit extract treatment group of Example 1,
도 2 및 도 3에서 보여지는 바와 같이, 인삼 열매 추출물 처리하였을 때에 혈관내피세포(HUVEC) 단층 배양 시스템(monolayer culture system)에서 대조군에 비하여 일산화질소(NO)를 유의적으로 증가시키는 효과가 나타났으며, 이 효과는 농도에 의존적이었다. 홍삼 대조군은 100 ㎍/ml 농도에서 일산화질소(NO)의 생성을 대조군 대비 약 1.5배 정도 증가시켰으며, 일산화질소 생성효소의 기질인 L-아르기닌은 250 μM, 500 μM 농도에서 각각 2.7배, 5.5 배 정도 증가시킨 반면, 인삼열매 추출물은 50 ㎍/ml, 100 ㎍/ml 농도에서 혈관이완의 신호전달 물질인 일산화질소(NO)의 생성을 대조군 대비 각각 4배, 12배 정도 증가시켰다. 즉, 인삼열매 추출물의 효과가 가장 좋았으며, 홍삼추출물의 효능과 비교하였을 때 100 ㎍/ml 농도에서 홍삼추출물 대비 약 8배 정도 그 효능이 뛰어남을 발견하였다. As shown in Figures 2 and 3, the treatment of ginseng fruit extract showed a significant increase in nitric oxide (NO) in the vascular endothelial cell (HUVEC) monolayer culture system compared to the control group This effect was concentration dependent. In the red ginseng control group, the production of nitric oxide (NO) was increased about 1.5 times compared to the control group at 100 ㎍ / ml, and L-arginine, a substrate of nitric oxide synthase, was 2.7-fold and 250-micron at 500 μM On the other hand, the ginseng fruit extract increased the production of nitric oxide (NO), a signaling substance for vasorelaxation at concentrations of 50 μg / ml and 100 μg / ml by 4 and 12 times, respectively, compared to the control. That is, the effect of ginseng fruit extract was the best, and when compared with the efficacy of red ginseng extract, it was found to be about 8 times more effective than the red ginseng extract at the concentration of 100 ㎍ / ml.
상기의 결과로부터 인삼열매 추출물을 섭취하면, 혈관내피세포에서 일산화질소(NO)의 생성이 증가하므로, 음경 해면체에서 혈관확장으로 인한 음경 발기를 증진시킬 수 있음을 알 수 있다.
Ingestion of ginseng fruit extract from the above results, it can be seen that since the production of nitric oxide (NO) in the vascular endothelial cells, it is possible to promote penile erection due to vasodilation in the corpus cavernosum.
[시험예 3] 인삼열매 추출물과 L-아르기닌을 복합 사용했을 때의 일산화질소 생성의 상승효과Test Example 3 Synergistic Effects of Nitric Oxide Production When Ginseng Fruit Extract and L-Arginine Combined
일산화질소 생성효소의 기질로 알려진 L-아르기닌과 일산화질소(NO)의 생성을 촉진시키는 인삼열매 추출물을 동시에 처리하였을 때, 일산화질소의 생성이 상승되는지 관찰하였다. When the ginseng fruit extract promoting the production of L-arginine and nitrogen monoxide (NO), which are known as substrates of nitric oxide synthase, was simultaneously treated, it was observed whether the production of nitric oxide was elevated.
탯줄에서 혈관내피세포를 분리 및 배양하고, 배양된 혈관내피세포에서의 일산화질소(NO)의 생성을 측정하였다. 구체적인 실험방법은 상기 시험예 2와 동일하며, 그 결과는 도 4에 나타내었다.Endothelial cells were isolated and cultured from the umbilical cord, and production of nitric oxide (NO) in the cultured vascular endothelial cells was measured. Specific experimental method is the same as in Test Example 2, the results are shown in FIG.
도 4에서 con은 대조군을 의미하며, L-arginine 500은 L-아르기닌 500 μM, GB 100은 인삼열매 추출물 100 ㎍/ml, L-arginine + GB은 L-아르기닌 500 μM + 인삼열매 추출물 100 ㎍/ml을 처리한 것을 의미한다.In Figure 4 con means a control, L-arginine 500 L-
도 4에서 보여지는 바와 같이, 인삼열매 추출물 100 ㎍/ml와 L-아르기닌 500 μM을 동시에 혈관내피세포에 처치하였을 때 일산화질소(NO)의 생성이 각각을 처치하였을 때보다 더 훨씬 증가하였음을 알 수 있으며, 이는 상승효과(Synergy Effect)로 볼 수 있다. As shown in FIG. 4, 100 g / ml of ginseng fruit extract and 500 μM of L-arginine were simultaneously treated with vascular endothelial cells, indicating that the production of nitric oxide (NO) was much higher than that of each treatment. This can be seen as a synergy effect.
상기의 결과로부터 일산화질소 생성 효소의 기질인 L-아르기닌과 인삼열매 추출물의 혼합 처방은 일산화질소의 생성을 급격하게 증가시키며, 따라서 인삼열매 추출물과 L-아르기닌의 혼합 처방은 음경해면체를 이완시켜 발기를 유도 및 지속시킴으로써 남성 성기능 개선에 큰 도움을 줄 수 있음을 알 수 있다.
From the above results, the mixed prescription of L-arginine and ginseng fruit extract, which are the substrates of nitric oxide-producing enzymes, dramatically increases the production of nitrogen monoxide. Therefore, the mixed prescription of ginseng fruit extract and L-arginine relaxes the corpus cavernosum. It can be seen that by inducing and sustaining can be a great help in improving male sexual function.
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20070046007 | 2007-05-11 | ||
KR1020070046007 | 2007-05-11 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080043488A Division KR101030608B1 (en) | 2007-05-11 | 2008-05-09 | Composition containing ginseng berry extract for improving sexual function |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110020889A KR20110020889A (en) | 2011-03-03 |
KR101241050B1 true KR101241050B1 (en) | 2013-03-11 |
Family
ID=40286914
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080043488A KR101030608B1 (en) | 2007-05-11 | 2008-05-09 | Composition containing ginseng berry extract for improving sexual function |
KR1020110012261A KR101241050B1 (en) | 2007-05-11 | 2011-02-11 | Composition containing ginseng berry extract for improving sexual function |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080043488A KR101030608B1 (en) | 2007-05-11 | 2008-05-09 | Composition containing ginseng berry extract for improving sexual function |
Country Status (1)
Country | Link |
---|---|
KR (2) | KR101030608B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11612629B2 (en) | 2018-08-20 | 2023-03-28 | Holistic Bio Co., Ltd. | Pharmaceutical composition for preventing or treating muscle diseases, containing ginseng berry extract as active ingredient |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100942794B1 (en) * | 2009-11-03 | 2010-02-18 | 한남대학교 산학협력단 | Arginine derivative and its salt showing the effect of improving sexual functions, composition for improving sexual functions comprising the same, and the manufacturing method thereof |
KR101481778B1 (en) * | 2014-03-17 | 2015-01-13 | 주식회사 브레인트로피아 | Composition containing the extract of ginseng berry containing increased ginsenoside Re for improving sexual function |
KR102180363B1 (en) | 2019-05-14 | 2020-11-19 | 주식회사 대화바이오 | An anti-impotence formula comprising black sesame and yeast hydrolysate |
KR20220011254A (en) | 2020-07-20 | 2022-01-28 | 이지원 | Composition containing sardinops extract for improving sexual function |
KR102651348B1 (en) | 2023-12-20 | 2024-03-26 | 주식회사 상상바이오 | Food composition for maintaining erection and improving prostate health |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010074683A (en) * | 1998-07-09 | 2001-08-09 | 멜빈 제이. 듀켓 | Natural composition and method for the treatment of sexual dysfunction |
-
2008
- 2008-05-09 KR KR1020080043488A patent/KR101030608B1/en active IP Right Grant
-
2011
- 2011-02-11 KR KR1020110012261A patent/KR101241050B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010074683A (en) * | 1998-07-09 | 2001-08-09 | 멜빈 제이. 듀켓 | Natural composition and method for the treatment of sexual dysfunction |
Non-Patent Citations (2)
Title |
---|
FEBS Letters, 581(13), 2007.04.30, pp.2423-2428 * |
FEBS Letters, 581(13), 2007.04.30, pp.2423-2428* |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11612629B2 (en) | 2018-08-20 | 2023-03-28 | Holistic Bio Co., Ltd. | Pharmaceutical composition for preventing or treating muscle diseases, containing ginseng berry extract as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
KR20110020889A (en) | 2011-03-03 |
KR101030608B1 (en) | 2011-04-20 |
KR20080100145A (en) | 2008-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Choy et al. | Natural products targeting ER stress pathway for the treatment of cardiovascular diseases | |
JP6514298B2 (en) | Composition for promoting circulation, preventing blood vessel aging and treating ischemic heart disease, comprising a ginseng berry extract | |
KR101241050B1 (en) | Composition containing ginseng berry extract for improving sexual function | |
JP2011512404A (en) | Composition comprising a Panax plant leaf extract or a treated Panax species plant leaf extract or a mixture of both for improving athletic performance, fatigue recovery and antioxidant activity | |
CA3023426A1 (en) | Dietary supplements and compositions for enhancing physical performance and energy levels | |
Manosroi et al. | Potent hypoglycemic effect of Nigerian anti-diabetic medicinal plants | |
KR20140089502A (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of Panax species plant leaf extract and processed Panax species plant leaf extract | |
CN101837066A (en) | Application of golden thread detoxication decoction as compound preparation in preparing IOD active medicaments | |
JP5435951B2 (en) | Extracts from the bark of Corinante species, their use, and drugs, diet foods and pharmaceuticals containing them | |
KR101093930B1 (en) | Novel use of scoparone | |
RU2519221C1 (en) | Biologically active composition for improvement of sexual function in men (versions) | |
KR20140089501A (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising processed Panax species plant leaf extract | |
WO2019114676A1 (en) | New medical use of persimmon leaf extract and of preparation of persimmon leaf extract | |
Pozdnyakov et al. | Anti-stress activity of some plants extracts of the North Caucasus flora | |
CN1919258B (en) | Application of schisandra chinensis in the preparation of medicine for preventing and reducing toxic and side effect of antitumor agent | |
KR102283093B1 (en) | Composition for prevention and treatment of metabolic diseases including ginger extract | |
Yoon et al. | The effects of new herbal formula (KBMSI-2) on penile erection and expression of nitric oxide synthase isoforms in streptozotocin-induced diabetic rat model | |
KR101743489B1 (en) | Composition for treatment of ischemic heart disease, facilitation of blood circulation and angiogenesis | |
KR101647654B1 (en) | Composition for treatment of ischemic heart disease, facilitation of blood circulation and angiogenesis | |
KR20220168960A (en) | pharmaceutical composition effective in the treatment and prevention of allergies including new varieties of licorice of Wongam and Sinwongam, and its therapeutic agent | |
KR101399895B1 (en) | A pharmaceutical comprising the extract of Acorus gramineus Soland for treating or preventing erectile dysfunction | |
Prasad et al. | In vitro alpha amylase inhibitory and antioxidant activity studies on the root of Chonemorpha fragrans (Moon) Alston | |
CN105520930A (en) | Applications of a class of flavane compounds in prevention or treatment of melanoma | |
KR20230067418A (en) | Pharmaceutical composition for preventing or treating erectile dysfunction comprising LCN2 protein or polynucleotide encoding it as an active ingredient | |
KR20090089813A (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising panax species plant leaf extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160223 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20161228 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190102 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 8 |